Loading candles…
Senores Pharmaceuticals Ltd was incorporated in 2015 and operates in the pharmaceutical industry. The company focuses on the development, manufacturing, and commercialization of complex generics and complex pharmaceutical products, including niche generic formulations. It specializes in specialty and underpenetrated therapeutic areas. Senores Pharmaceuticals develops products certified by global food and drug authorities and combines in-house research and development with advanced manufacturing capabilities. The company operates in regulated markets across the United States, Canada, the United Kingdom, and several emerging markets.
This page is a live market overview for SENORES PHARMACEUTICALS L (SENORES) on the NSE. As a listed security, SENORES PHARMACEUTICALS L is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SENORES before placing trades on tick2trade.
As of the latest feed, SENORES last traded at ₹1,342.6 on NSE, up ₹14.1 (1.06%) from the previous close of ₹1,328.5. Today's session range is ₹1,310 – ₹1,359.9, against a 52-week band of ₹632.05 – ₹1,509.8. Traded volume today stands at 2.18L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SENORES in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SENORES is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SENORES PHARMACEUTICALS L before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SENORES. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SENORES option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters | 27 Jul 2026 |
| Audited Results - Q4 & FY26 | To consider and approve Audited Consolidated and Standalone Financial Results Of The Company For The Quarter And financial year Ended March 31, 2026 And To T… | 14 May 2026 |
| Unaudited Results - Q3-FY26 | Senores Pharmaceuticals Limited has informed the exchange that the meeting of the Board of Directors of the Company is scheduled on January 20, 2026 ,inter a… | 20 Jan 2026 |
| Other | Senores Pharmaceuticals Ltd has informed the exchange that the meeting of the Board of Directors of the Company is scheduled on 07/01/2026, inter alia, to co… | 7 Jan 2026 |
| Results - Q2 & FY25 | To consider and approve the financial results for the quarter and half year ended September 30, 2025 and to transact other business matters | 6 Nov 2025 |
| Unaudited Results - Q1-FY25 | Senores Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on July 23, 2025 to consider and approve the Un-audited Standalone a… | 23 Jul 2025 |
| Audited Results - Q4 & FY25 | Senores Pharmaceuticals Limited has informed the Exchange that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 ,inter alia, t… | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.